Breast

Papers
(The TQCC of Breast is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis1265
Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects114
Novel models based on machine learning to predict the prognosis of metaplastic breast cancer98
Describing quality of life trajectories in young Hispanic women with breast cancer: 5-year results from a large prospective cohort87
A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy81
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer78
Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain56
Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials55
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer51
A multidisciplinary approach to optimizing care of patients treated with alpelisib47
Patient-reported outcomes in bilateral prophylactic mastectomy with breast reconstruction: A narrative review42
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial40
Seizing the moment: The time for harnessing electronic patient-reported outcome measures for enhanced and sustainable metastatic breast cancer care is now38
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort37
Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial36
Meeting the proposal for service improvement for pregnant women with cancer36
Response to comment on: “Global guidelines for breast cancer screening: A systematic review”36
The continuing conundrum in oligometastatic breast carcinoma: A real-world data36
No association between breast pain and breast cancer35
Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study35
Surgical Outcomes Of Post-Mastectomy Radiotherapy Following Immediate Prosthetic Breast Reconstruction: Six-Year Experience34
Using Radio-Occult Lesion Localization (Roll) Techniques To Identify The Clipped Node In Targeted Axillary Dissections (Tad)34
Optimising post-operative radiation therapy after oncoplastic and reconstructive procedures32
The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin31
Towards consensus on managing high mammographic density in population breast screening?31
Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence30
Editorial Board30
Title Page29
Trends in the pre-operative diagnosis and surgical management of axillary lymph node metastases in women with screen-detected breast cancer29
General Information28
Reproductive outcomes in young breast cancer survivors treated (15–39) in Ontario, Canada: a population-based study27
Totality of evidence for ABP 980, a trastuzumab biosimilar: results of chemo-synergy studies in combination with pertuzumab26
P243 Is the indian population ready for acosog z0011 protocol?26
Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring26
Assessing the Impact of the COVID-19 outbreak on the oncological practice regarding metastatic breast cancer patients treated with CDK4/6 inhibitors25
P255 Breast cancer surgery with ‘pecs block’ technique in the oldest old24
P251 Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2−breast cancer at a single cancer center24
Index24
P277 Sick leave and predictive factors for sick leave at 12 months after breast cancer surgery in the randomized controlled physical activity trial (PhysSURG-B)23
P273 The lived experiences of telehealth system use among women with breast cancer23
P271 The impact of extraordinary situations such as war on tumor characteristics and time before the start of treatment in patients with non-metastatic breast cancer (BC)23
P280 How often do breast cancer patients seek traditional Chinese medicine in North China?22
P278 Early Integrated Rehabilitation Helped Breast Cancer Patients to Start Healthy Lifestyle– A Comparison Between the Intervention and Control Group in a Prospective Study22
P291 Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers21
PO81 NURSES AS PATIENT ADVOCATES IN RESOURCE-RESTRICTED COUNTRIES - EXPERIENCE OF GEORGIA21
IMPACT OF THE REGIONAL AND SYSTEMIC TREATMENT IN BREAST CANCER PATIENTS WITH LOCAL RECURRENCE21
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial21
ROLE OF HEMI-BODY RADIATION IN BREAST CANCER WITH DISSEMINATED BONE METASTASIS21
PO100 HER2 LOW METASTATIC BREAST CANCER PATHOLOGICAL AND CLINICAL CHARACTERISTICS: A SINGLE MEXICAN INSTITUTION EXPERIENCE21
P289 Retrospective study of pregnancy outcome after breast cancer21
PO85 MEETING THE NEEDS OF WOMEN WITH ADVANCED BREAST CANCER IN THE SUPPORT SETTING21
DOES THE LOCATION OF BRAIN METASTASES AFFECT THE PROGNOSIS IN BREAST CANCER PATIENTS?21
PR86 THE TREATMENT JOURNEY OF ABC PATIENTS IN MOROCCO: NEEDS AND CHALLENGES FROM A PATIENT ‘S PERSPECTIVE, 2 CASE REPORTS21
EMOTIONAL DISTRESS, BRAIN FUNCTIONING, SOCIAL WELL-BEING AND BIOBEHAVIORAL PROCESSES IN METASTATIC BREAST CANCER PATIENTS: OUTCOMES OF THE DISTRESSBRAIN PROJECT20
PO120 CAN A BREAST CANCER REGISTER MEASURE ADHERENCE TO NATIONAL ADVANCED BREAST CANCER (ABC) TREATMENT GUIDELINES IN CLINICAL PRACTICE?20
PR131 SACITUZUMAB GOVITECAN – REAL-WORLD EXPERIENCE OF A PORTUGUESE CANCER CENTER20
PO103 BRAIN IMAGING SURVEILLANCE IN ASYMPTOMATIC PATIENTS WITH METASTATIC BREAST CANCER: PATIENT AND PHYSICIAN PERSPECTIVES20
RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain20
PO118 RESULTS OF ANTI-HER 2 THERAPIES AFTER BRAIN METASTASES ON THE PROGNOSIS IN BREAST CANCER PATIENTS20
PO115 REAL WORLD EFFECTIVENESS OF EVEROLIMUS-BASED THERAPY IN HORMONE-RECEPTOR-POSITIVE METASTATIC BREAST CANCER AFTER PROGRESSION ON CDK4/6 INHIBITOR20
PR126 ANTIOXIDANT CORRECTION OF HEMATOLOGICAL TOXICITY DURING CHEMOTHERAPY FOR METASTATIC BREAST CANCER20
BP140 UNMASKING THE IMPACT OF INPATIENT PALLIATIVE CARE CONSULTATION ON PATIENT OUTCOMES IN ADVANCED BREAST CANCER PATIENTS: A RETROSPECTIVE REVIEW19
OR139 ENHANCING PATIENT CARE: INTERIM DATA ANALYSIS AND PATIENT EXPERIENCE OF PERSONALIZED ELECTRONIC SYMPTOM MONITORING LED BY A SPECIALIST NURSE FOR ENGAGEMENT IN TREATMENT AND IMPROVED QUALITY OF L19
PO133 RADIATION INDUCED HYPOTHYROIDISM IN LOCALLY ADVANCED BREAST CANCER19
Response to Soran et al.19
PO136 IMPACT OF ISOLATED SOLITARY BREAST CANCER LIVER METASTASIS SURGICAL RESECTION ON COMMON PATIENT HEALTH STATUS AND ABILITY TO PROCEED CHEMOTHERAPY19
Predicting the survival benefit of local surgery in patients aged 70 years or older with stage IV breast cancer: A population-based analysis18
Radiation dose distribution in cardiac valves in left-sided breast cancer radiotherapy18
The natural history of ductal carcinoma in situ (DCIS) in simulation models: A systematic review18
Nodal response to primary systemic therapy predicts prognosis of cN3c breast cancer patients receiving multimodality therapy18
Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer18
P131 Real World Evidence of the Impact at Neoadjuvant Chemotherapy Treatment on the Prognosis of Patients with Early Breast Cancer18
PR138 MALIGNANT PHYLLODES TUMOR WITH THIRD LOCAL RECURRENCE AND MULTIPLE DISTANT METASTASES: A CASE REPORT18
SABR in oligometastatic breast cancer: Current status and future directions18
Role of time factor between External Beam Radiotherapy alone versus External Beam in combination with brachytherapy boost in breast cancer patients after breast conserving surgery18
P143 Kinetics of Ejection Fraction Decline as A Predictive Factor for Cardiotoxicity in Trastuzumab-treated Early Breast Cancer Patients: Single Institution Experience18
Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers18
Analysis of primary endocrine therapy in breast cancer patients over 70 years from a single unit in South Africa: analysis of those that choose no surgery first. Highlighting COVID-19 sensitive issues17
A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, and immunogenicity of ABP 980 and pertuzumab combined in a single infusion in healthy subjects17
P152 The impact of the TailorX and RxPonder studies and the use of Oncotype Dx in clinical practice: A single Breast Cancer Center experience17
One size fits all? Novel pulse biopsy platform offers improved needle control, high tissue yield and multiple needle options – pre-clinical results17
P154 Characteristics and prognosis of BRCA-associated breast cancers: Results from a single-center observational study in Thailand16
Effectivness of breast-conserving treatment for minimal residual tumors after neoadjuvant breast cancer therapy16
Implementation of a pathology-supported genetic testing framework for return of research results to family members of deceased breast cancer patients with somatic TP53 variants16
P157 MammaPrint 8-year follow up results in patients with early breast cancer from a single-center Italian cohort study16
P171 Do Tumor Infiltrating Lymphocytes and Programmed Cell Death Ligand -1 have a Predictive and Prognostic Role in Advanced Triple Negative Breast Cancers – Results of a Study from a Developing Count16
P184 Unsatisfactory cosmetic results after oncoplastic breast-conserving surgery16
Hospital vs community screening for breast cancer16
P176 Is the ≥1-cm width of resection margin in phyllodes tumor necessary to reduce recurrence?16
Factors affecting sentinel lymph node metastasis in patients with breast cancer undergoing sentinel lymph node biopsy before or after systemic therapy16
Abstract Presenters15
P191 Skin-sparing or nipple-sparing mastectomy with one-stage or two-stage reconstruction: analysis of early outcomes and patient’s satisfaction15
P203 Comparing the combine flap fixation and Harmonic scalpel technique with the Harmonic scalpel alone in reducing seroma formation after mastectomy in breast cancer patient: A pilot study for a RCT15
Retrospective evaluation of immediate postmastectomy breast reconstruction with Tiloop BRA. Our experience with 103 patients15
The long term outcome of patients on primary endocrine therapy15
Angiosome theory findings using new protocol of CT-angiography improves outcomes in DIEP-flap reconstruction surgery in breast cancer patients15
IN18 BIOLOGY 1.0 – INTERPRETING AN NGS REPORT14
IN37 INEQUITIES IN ACCESS TO NEW CANCER DRUGS: ROLE OF REGULATORS AND CLINICAL TRIALS14
CURRENT STANDARD OF CARE FOR HER2+ ABC14
BP51 ABC4NURSES: ACO-DESIGN PROJECT TO DEVELOP, DELIVER AND EVALUATE AN ONLINE EDUCATION PROGRAMME FOR NURSING CARING FOR PEOPLE WITH ADVANCED BREAST CANCER14
IN27 REVISITING OLIGOMETASTATIC DISEASE14
IN29 NEW IMAGING TECHNOLOGIES AND STRATEGIES IN ABC14
IN34 OPTIMAL MANAGEMENT OF AN OLDER FRAIL PATIENT WITH ADVANCED BREAST CANCER14
SBRT AND NEW RADIOTHERAPY TECHNIQUES FOR METASTATIC DISEASE13
PO68 “I AM STILL ALIVE”: PEER SUPPORT GROUP FOR OLDER WOMEN WITH METASTATIC BREAST CANCER IN NIGERIA13
EFFECTIVE ADVOCACY FOR WOMEN WITH METASTATIC BREAST CANCER: A EUROPEAN PERSPECTIVE13
PO54 HOME BASED CARE FOR TERMINAL CANCER PATIENTS: STUDY FROM RURAL PART OF INDIA13
ADVANCED BREAST CANCER (ABC) PATIENT SUPPORT BY WEB CONFERENCING USING ZOOM13
GLOBAL SURVEY OF 104 CANCER PATIENT ORGANISATIONS REVEALS DEVASTATING IMPACT OF COVID-1913
A PATIENT’S JOURNEY: BRIDGING THE GAP FROM METASTATIC BREAST CANCER DIAGNOSIS TO ACTIVE INVOLVEMENT AS A PEER NAVIGATOR13
PO67 “GUIDING TOWARDS BETTER CARE: BREAST CANCER NAVIGATORS’ PROGRAM IMPLEMENTATION FOR INCREASING PATIENTS’ SATISFACTION AT A COMPREHENSIVE CANCER CENTER”13
French college of gynecologists and obstetricians (CNGOF) recommendations for clinical practice: Place of breast self-examination in screening strategies12
Preoperative breast MRI influences surgical management in patients with invasive lobular carcinoma12
SA 6.4 Breast surgery for local recurrence12
More Breast-Conserving Surgery in Australia in T2 Breast Cancers Over the Last 20 Years12
Factors influencing the time to diagnosis and treatment of breast cancer among women in low- and middle-income countries: A systematic review12
Axillary surgery in node-positive breast cancer12
Artificial intelligence for preoperative diagnosis of sentinel lymph node biopsy in early breast cancer.12
SA 8.1 Assessing HER2 heterogeneity12
Title Page12
Editorial Board12
De-escalation of loco-regional treatments: Time to find a balance12
SA 7.3 Limited axillary surgery concepts to determine nodal pathologic complete response12
SA 9.1 Optimal neoadjuvant and adjuvant therapy for patients with early triple negative breast cancer12
De-escalation of early breast cancer therapy: Umberto Veronesi’s legacy11
Can we prevent brain metastases?11
P001 Scalp cooling system for breast cancer patients treated by adjuvant or neo-adjuvant chemotherapy11
Axillary surgery in node-positive breast cancer11
Accelerating progress from advanced to early breast cancer (SERDS, PI3Kinhibitors, other novel agents)11
The contribution of radiation therapy to personalised care of patients with early breast cancer11
Adjuvant endocrine therapy for pre- and postmenopausal women11
Integrating CDK 4-6 in the treatment of patients with early breast cancer11
Type/timing of reconstruction when post-mastectomy radiotherapy is planned11
AA2 Overtreatment in early breast cancer – who is at risk?11
P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial11
P012 Survival outcomes and toxicities of adjuvant docetaxel-cyclophosphamide for four cycles in node negative triple negative and HER2 positive Chinese breast cancer patients: A 10 year follow up stud11
Neoadjuvant and adjuvant treatment for triple negative breast cancer11
P031 Preoperative mammocartography and mammometry for the needs of oncoplastic approaches10
Lifestyle and sexual health10
P037 EGFR overexpression is related to immunohistochemical biomarkers in breast cancer10
P036 Classification of HER2-negative breast cancers by ERBB2 copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations10
Tolerance and outcome of hypofractionated whole breast irradiation in young women: from controversies to evidence10
P023 Male breast cancer: a single center report of histopathological sybtypes and outcomes10
P027 Establishment of a Thai patient-derived breast cancer organoid biobanking for drug screening in a single medical center in Thailand10
P042 MicroRNA signature abnormalities in breast cancer cells can facilitate overexpression of chemokines and their receptors responsible for recruitment of stromal cells into tumor microenvironment10
P075 Evaluation of personality traits of breast cancer patients in the context of their surgical therapy10
P057 Relationship between TP53 mutations and mammographic and ultrasonographic findings in breast cancer10
PARP inhibitors in treatment of early stage breast cancer10
Accelerating progress from advanced to early breast cancer for TNBC10
Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study10
Single nucleotide polymorphisms rs17335780 and rs11979255 of the epidermal growth factor receptor (EGFR) correlate with tumor size in breast cancer10
Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via AKT/mTOR signaling pathway9
Single-cell transcriptome sequencing analysis reveals gynaecomastia to breast cancer transition9
Tumor angiogenesis: miRNAome abnormalities deregulate expression of angiogenic genes in breast cancer cells and contribute to increased formation of new but imperfect blood vessels9
Effects of IORT and EBRT methods on local recurrence control in breast cancer patients using Weibull regression model9
Implementation of 26 Gy in five fractions over 1 week adjuvant radiotherapy for breast cancer: Prospective report of acute skin toxicity and consideration of resource implications9
Marked reduction in the risk of dementia in patients with breast cancer: a nationwide population-based cohort study9
E-cadherin expression in triple-negative invasive ductal breast carcinoma9
P092 Radiation induced hypothyroidism in breast cancer9
Role of hypofractionated tumor bed boost in the era of short course radiotherapy in early stage breast cancer9
Reply to Letter to Editor: “HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?”9
Expression of RANK-c in ER-/HER2+ breast cancer cells affect aggressiveness through altering the NF-κB equilibrium9
P090 Dosimetric Evaluation of the Heart and Left Anterior Descending Artery Dose in Radiotherapy for Japanese patients with Breast Cancer9
P098 Adjuvant radiotherapy after radical surgery and immediate breast reconstruction9
P114 Characteristics of residual tumor after neoadjuvant chemotherapy (nact)may predict outcomes in patients with triple negative breast cancer (tnbc)9
Efficacy of fulvestrant in hormone refractory metastatic breast cancer (mBC): a Canadian province experience9
Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?8
SA 2.1 ctDNA dynamics for early assessment of recurrence risk8
SL 1 The future of innovation: Why arewe conducting clinical trials in countries that are unlikely to be able to afford innovative drugs?8
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program8
The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis8
Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)8
Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis8
SA 1.1 Surgery of patients with early breast cancer: Quo vadis?8
Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy8
SA 3.1 Understanding the anti-cancer immune response: Innate and adaptive responses to cancer cells8
High risk surveillance outcomes in women with breast cancer gene mutations.8
Digital breast tomosynthesis versus X-ray of the breast specimen for intraoperative margin assessment: A randomized trial8
Exploring breast surgeons’ reasons for women not undergoing immediate breast reconstruction8
Artificial intelligence to de-escalate loco-regional breast cancer treatment8
Prognosis of pregnancy after breast cancer diagnosis according to the type of treatment: A population-based study in Korea by the SMARTSHIP group8
SA 1.3 What’s new in systemic treatment of patients with early breast cancer8
Accelerating progress to innovation for patients: Trial design and risk stratification8
SA 4.2 Local treatment in patients with high risk hereditary breast cancer8
Utility of magnetic resonance imaging (MRI) in the management of breast carcinoma8
Editorial Board8
BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications8
Editorial Board8
PR129 HORMON POSITIVE BREAST CANCER WITH EARLY RELAPSE7
Optimal localization strategies for non-palpable breast cancers –A network meta-analysis of randomized controlled trials7
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study7
RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa7
Family history of breast cancer, mammographic breast density and breast cancer risk: Findings from a cohort study of Korean women7
Extracellular volume measured by whole body CT scans predicts chronic cardiotoxicity in breast cancer patients treated with neoadjuvant therapies based on anthracyclines: A retrospective study7
Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histology7
Potential immune response to breast implants after immunization with COVID-19 vaccines7
Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score7
PO83 INCLUSION BY DESIGN: RECOMMENDATIONS FOR BUILDING EQUITY IN CLINICALTRIALS THROUGH THE LENS OF METASTATIC BREAST CANCER7
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicente7
Breast magnetic resonance imaging as a problem solving tool in women recalled at biennial screening mammography: A population-based study in the Netherlands7
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer7
Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective7
Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study7
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer7
Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up7
Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target7
Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials7
Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis7
Editorial Board7
Diagnostic accuracy of intraoperative methods for margin assessment in breast cancer surgery: A systematic review & meta-analysis7
Assessment and reimbursement of gene expression tests in breast cancer in Europe – a comparative policy analysis6
Management and outcomes for older women with early breast cancer treated with primary endocrine therapy (PET)6
Is the skin microbiota a modifiable risk factor for breast disease?: A systematic review6
Future potential targets of antibody-drug conjugates in breast cancer6
Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D6
Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review6
Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis6
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)6
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cance6
Axillary lymph node dissection: Dead or still alive?6
Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study6
Radio-frequency identification (RFID) tag localisation of non-palpable breast lesions a single centre experience6
Meta-analysis of intraoperative electron radiation therapy for partial breast irradiation in early breast cancer6
Differences in total cognition and cerebrovascular function in female breast cancer survivors and cancer-free women6
Adenosquamous proliferation in radial sclerosing lesions: Histologic spectrum and key features in systematic review of 247 lesions6
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study6
Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitals6
Contouring variation affects estimates of normal tissue complication probability for breast fibrosis after radiotherapy6
Mammographic density and interval cancers in mammographic screening: Moving towards more personalized screening6
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data6
Explaining risks and benefits of loco-regional treatments to patients6
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?6
Postoperative complications of hypofractionated and conventional fractionated radiation therapy in patients with implant-based breast reconstruction: A systematic review and meta-analysis6
Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up6
Preoperative non-palpable breast lesion localization, innovative techniques and clinical outcomes in surgical practice: A systematic review and meta-analysis6
A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer6
Factors associated with breast lymphedema after adjuvant radiation therapy in women undergoing breast conservation therapy5
Decisional conflict in breast cancer patients considering immediate breast reconstruction5
The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review5
Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer5
A patient-led survey on information and communication needs of patients with metastatic breast cancer in Ireland and Northern Ireland (CTRIAL-IE 23–05)5
How I treat HER2-low advanced breast cancer5
Treatment of oligometastatic breast cancer: The role of patient selection5
Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?5
Acceptance of outpatient enhanced recovery after surgery (ERAS©) protocols for implant-based breast reconstruction nudged on by the COVID-19 pandemic5
Breast cancer patients with a pre-existing mental illness are less likely to receive guideline-recommended cancer treatment: A systematic review and meta-analysis5
The underused potential of breast conserving therapy after neoadjuvant system treatment – Causes and solutions5
Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer5
Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis5
The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy5
0.72175121307373